AI
Wednesday, September 19, 2012 11:20:30 AM
PPHM’s 2012 Annual Report => the theme for Peregrine at this point is clearly “Transformation”. I received mine on Sept. 18, 2012…
Peregrine
Pharmaceuticals
“A Time of
. . .Transformation”
Then, the inside cover…
• “Transforming Our Business”
• “Transforming Patients’ Lives”
• “Transforming Our Future”
“With two Phase III-ready programs, an outstanding pipeline, and a successful commercial manufacturing business, Peregrine is transitioning from an early-stage to a late-stage development company. The company is in a unique position of strength on several fronts with multiple partnering, development, and revenue-generating opportunities. The opportunities can help not only to transform the company, but potentially the lives of patients with life-threatening diseases.”
= = = = = = = = = =
Then follows CEO Steve King’s 2-page Aug.2012 letter to shareholders, with these section bullets:
”This is truly a transformative time for Peregrine…”
• Bavituximab: Positioned for Phase III Development
• Casting a Broad Net in Bavituximab’s Development
• Cotara: Advancing Discussions Focused on Future Development
• PS-Imaging: Expanding Our Possibilities
• Avid Bioservices: A Record Year and Readying for Commercialization
• Becoming a Late-Stage Development Company
”What we are seeing today is the culmination of multiple years of hard work and dedication by our employees, our clinical investigators, the support of our stockholders, and most importantly, the patients that have participated in our clinical trials, in what can only be described as transformational. Simply put, we are enthusiastic about our future, about the strengthening of our pipeline, the increasing acceptance of this novel technology platform, and the growing set of clinical data that in the end we are hopeful will be a new and improved treatment option for patients.”
Steven W. King
President & CEO
Aug. 2012
= = = = = = = = = = = = = = = = = =
Oct18 2012 10amPDT: Annual S/H Meeting (Corp-HQs, Tustin) - def. proxy iss. 8-27-12 (Schd14A): http://tinyurl.com/8kltugd
Latest 10K 4-30-12 iss. 7-16-12: http://tinyurl.com/79o57b2 PR: http://tinyurl.com/c8nytow (Cash 4-30-12 $18.0mm)
Latest 10Q 7-31-12 iss. 9-10-12: http://tinyurl.com/9sd8nua PR: http://tinyurl.com/9f85fdo (Cash 7-31-12 $19.0mm)
ALL SEC filings for PPHM: http://tinyurl.com/6d4jw8
Peregrine
Pharmaceuticals
“A Time of
. . .Transformation”
Then, the inside cover…
• “Transforming Our Business”
• “Transforming Patients’ Lives”
• “Transforming Our Future”
“With two Phase III-ready programs, an outstanding pipeline, and a successful commercial manufacturing business, Peregrine is transitioning from an early-stage to a late-stage development company. The company is in a unique position of strength on several fronts with multiple partnering, development, and revenue-generating opportunities. The opportunities can help not only to transform the company, but potentially the lives of patients with life-threatening diseases.”
= = = = = = = = = =
Then follows CEO Steve King’s 2-page Aug.2012 letter to shareholders, with these section bullets:
”This is truly a transformative time for Peregrine…”
• Bavituximab: Positioned for Phase III Development
• Casting a Broad Net in Bavituximab’s Development
• Cotara: Advancing Discussions Focused on Future Development
• PS-Imaging: Expanding Our Possibilities
• Avid Bioservices: A Record Year and Readying for Commercialization
• Becoming a Late-Stage Development Company
”What we are seeing today is the culmination of multiple years of hard work and dedication by our employees, our clinical investigators, the support of our stockholders, and most importantly, the patients that have participated in our clinical trials, in what can only be described as transformational. Simply put, we are enthusiastic about our future, about the strengthening of our pipeline, the increasing acceptance of this novel technology platform, and the growing set of clinical data that in the end we are hopeful will be a new and improved treatment option for patients.”
Steven W. King
President & CEO
Aug. 2012
= = = = = = = = = = = = = = = = = =
Oct18 2012 10amPDT: Annual S/H Meeting (Corp-HQs, Tustin) - def. proxy iss. 8-27-12 (Schd14A): http://tinyurl.com/8kltugd
Latest 10K 4-30-12 iss. 7-16-12: http://tinyurl.com/79o57b2 PR: http://tinyurl.com/c8nytow (Cash 4-30-12 $18.0mm)
Latest 10Q 7-31-12 iss. 9-10-12: http://tinyurl.com/9sd8nua PR: http://tinyurl.com/9f85fdo (Cash 7-31-12 $19.0mm)
ALL SEC filings for PPHM: http://tinyurl.com/6d4jw8
